感染

订阅

MedSci主页 / 所有栏目 / 感染

FDA授予RLF-100（Aviptadil）快速通道资格：治疗COVID-19呼吸窘迫

2020-06-25 Allan MedSci原创

Covid-19RLF-100Aviptadil
关注

制药公司NeuroRx近日宣布，美国FDA已授予研究性新药RLF-100（Aviptadil）快速通道资格，用以治疗与COVID-19相关的急性肺损伤/急性呼吸窘迫综合征。

制药公司NeuroRx近日宣布，美国FDA已授予研究性新药RLF-100（Aviptadil）快速通道资格，用以治疗与COVID-19相关的急性肺损伤/急性呼吸窘迫综合征。RLF-100是一款合成型人血管活性肠肽（VIP），可减少肺部炎症并保护II型肺泡细胞，这些细胞被认为是SARS-CoV-2侵袭肺部的途径。

作为NeuroRx加入快速通道计划的一部分，FDA已要求NeuroRx提交可公开获得的患者入组政策，以便患者可以进入RLF-100（Aviptadil）的III期临床试验。

在包括迈阿密大学、休斯敦卫理公会医院、加利福尼亚大学欧文分校、纽约大学朗格尼医学中心在内的主要医学中心，NeuroRx正在对RLF-100进行II/III期临床试验。这项多中心临床试验招募了重症COVID-19患者，这些患者存在呼吸衰竭。这些研究的目的旨在通过RLF-100拯救II型肺泡细胞来降低患者死亡率。

 

原始出处：

https://www.firstwordpharma.com/node/1735200

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746693, encodeId=ee4e1e4669375, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Fri Oct 30 01:37:59 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801121, encodeId=03d0801121ba, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200819/64fbd2072f9a45e4ab1d483ac903cef2/6094007d789849e39a3a1f25435a6f41.jpg, createdBy=72732561091, createdName=125619a9m67暂无昵称, createdTime=Fri Jul 03 23:09:21 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495277, encodeId=289514952e714, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 27 00:37:59 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582273, encodeId=8ce015822e393, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Sat Jun 27 00:37:59 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799773, encodeId=9dd7e997738c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Jun 25 09:59:51 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-10-30 chendoc254

    #VIP#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1746693, encodeId=ee4e1e4669375, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Fri Oct 30 01:37:59 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801121, encodeId=03d0801121ba, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200819/64fbd2072f9a45e4ab1d483ac903cef2/6094007d789849e39a3a1f25435a6f41.jpg, createdBy=72732561091, createdName=125619a9m67暂无昵称, createdTime=Fri Jul 03 23:09:21 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495277, encodeId=289514952e714, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 27 00:37:59 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582273, encodeId=8ce015822e393, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Sat Jun 27 00:37:59 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799773, encodeId=9dd7e997738c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Jun 25 09:59:51 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-07-03 125619a9m67暂无昵称

    学到了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1746693, encodeId=ee4e1e4669375, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Fri Oct 30 01:37:59 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801121, encodeId=03d0801121ba, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200819/64fbd2072f9a45e4ab1d483ac903cef2/6094007d789849e39a3a1f25435a6f41.jpg, createdBy=72732561091, createdName=125619a9m67暂无昵称, createdTime=Fri Jul 03 23:09:21 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495277, encodeId=289514952e714, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 27 00:37:59 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582273, encodeId=8ce015822e393, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Sat Jun 27 00:37:59 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799773, encodeId=9dd7e997738c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Jun 25 09:59:51 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-06-27 Eleven14

    #快速通道资格#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1746693, encodeId=ee4e1e4669375, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Fri Oct 30 01:37:59 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801121, encodeId=03d0801121ba, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200819/64fbd2072f9a45e4ab1d483ac903cef2/6094007d789849e39a3a1f25435a6f41.jpg, createdBy=72732561091, createdName=125619a9m67暂无昵称, createdTime=Fri Jul 03 23:09:21 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495277, encodeId=289514952e714, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 27 00:37:59 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582273, encodeId=8ce015822e393, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Sat Jun 27 00:37:59 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799773, encodeId=9dd7e997738c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Jun 25 09:59:51 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-06-27 12498cf9m40(暂无昵称)

    #呼吸窘迫#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1746693, encodeId=ee4e1e4669375, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Fri Oct 30 01:37:59 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801121, encodeId=03d0801121ba, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200819/64fbd2072f9a45e4ab1d483ac903cef2/6094007d789849e39a3a1f25435a6f41.jpg, createdBy=72732561091, createdName=125619a9m67暂无昵称, createdTime=Fri Jul 03 23:09:21 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495277, encodeId=289514952e714, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 27 00:37:59 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582273, encodeId=8ce015822e393, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Sat Jun 27 00:37:59 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799773, encodeId=9dd7e997738c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Jun 25 09:59:51 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-06-25 医鸣惊人

    学习

    0

相关资讯

一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验

EIDD-2801是一种新型核糖核苷类似物，可抑制多种RNA病毒的复制，包括SARS-CoV-2。

AJOG：COVID-19感染对孕妇妊娠结局的影响

COVID-19世界大流行，让全世界的人民人心惶惶，能避免去医院就不去医院。但有一类人无法避免去医院，那就是待产的孕妇。本研究旨在报告COVID-19感染对孕妇妊娠结局和临床预后的影响。

NEJM：全基因组关联研究发现重症COVID-19遗传易感基因，且A型血感染者更易呼吸衰竭

近日，来自挪威奥斯陆大学的研究团队在NEJM上发表了其对重症Covid-19与呼吸衰竭的全基因组相关性的最新研究结果。

瑞德西韦仿制药获批，定价公布

瑞德西韦仿制药获批，定价公布，总治疗成本低至195美元（约合人民币1379.8元）……

吉利德开始测试吸入型瑞德昔韦

吉利德（Gilead）宣布了一项计划，开始对吸入型抗病毒药物瑞德昔韦（remdesivir）进行试验，以期在COVID-19的治疗途径中尽早使用该药物。

Crit Care：急性肾功能不全的患病率及其对COVID-19的影响

COVID-19患者异常尿液分析和肾功能不全的发生率很高，并且AKI与COVID-19患者的严重程度和预后密切相关。因此，需要提高COVID-19患者对肾功能不全的认识。

拓展阅读

Science：Bruton酪氨酸激酶治疗重症COVID-19患者的疗效

重症COVID-19患者具有提示巨噬细胞激活的超炎性免疫反应。Bruton酪氨酸激酶(BTK)调节巨噬细胞信号转导和活化。

Lancet发布中国研究成果，瑞德西韦治疗重症Covid-19患者未见明显益处

与安慰剂相比，瑞德西韦治疗COVID-19重症患者，未带来临床改善时间、死亡率或病毒清除时间等获益。

FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验

罗氏公司旗下的Genentech本周一宣布，FDA已批准了一项III期临床试验（COVACTA研究）。